Skip to main content

Overview

Szilárd Kiss is the Associate Dean of Clinical Compliance, Chair of the Graduate Faculty Council, Chief of the Retina Service, Vice-Chair of Research, Vice-Chair of Tele-Ophthalmology, Vice-Chair of Clinical Compliance and Associate Professor of Ophthalmology at Weill Cornell Medical College in New York City.  Szilárd received an undergraduate degree with honors from Columbia College and medical school training at Columbia University Vagelos College of Physicians & Surgeons. Szilárd completed an ophthalmology residency and surgical vitreoretinal fellowship at Harvard Medical School and the Massachusetts Eye & Ear Infirmary, where he was selected by the faculty to serve as the Chief Retina Fellow.  Szilárd’s research career started as an undergraduate at Columbia College where, in conjunction with the National Aeronautics and Space Administration (NASA) and the Department of Defense, he evaluated the implications of microgravity on early developmental patterning with scientific experiments launched on the space shuttle Discovery (STS-70) and the space shuttle Columbia (STS-78).  Currently, Szilárd’s clinical and translational research efforts focus on four broad areas: ocular gene and cellular therapy, novel therapeutic targets for ocular neovascularization, complex vitreoretinal surgical techniques, and retinal imaging.  Szilárd has participated as a principal investigator in over three-dozen prospective clinical trials and laboratory investigations.  He has authored over 270 scientific publications, given over 250 invited lectureships worldwide, and serves on the Editorial Board and as a scientific reviewer to a number of major journals. In addition to his scientific efforts, Szilárd has garnered a reputation as a world renowned medical and surgical vitreoretinal specialist; his clinical practice draws patients from all regions of the world.  For his academic and clinical work, Szilárd has won numerous academic and scientific awards including the Schepens Eye Research Institute Joint Clinical Research Center Pilot Project Grant, the Heed Ophthalmic Foundation Fellowship Award, the Ronald G. Michels Foundation Fellowship Award, the Paul Kayser International Fellowship Award, American Society of Retina Specialists Rhett Buckler Award, and the Research to Prevent Blindness Physician-Scientist Award.  For his contributions to ophthalmology, Szilárd has received the Honor and Senior Honor Awards from the American Society of Retina Specialists and the Honor Award from the American Academy of Ophthalmology. Szilárd was also among a select group of retina specialists worldwide (and the youngest) to be elected by his peers as a Charter Member of the Retina Hall of Fame. Szilárd has also been named to several regional, national and international Top Doctors lists, including The Ophthalmologist Power List Top 40 Under 40 Ophthalmologist Worldwide, OSN Retina 150 Leading Innovators in Surgical and Medical Retina, Castle Connolly’s Top Doctors, and New York Super Doctors.

Highlights

  1. 1
    Ophthalmology · 2020
    PMID: 32345477DOIFirst author46 citations
  2. 2
    EClinicalMedicine · 2023
    PMID: 38152412PMCID: PMC10751837DOISenior author79 citations
  3. 3
    Journal of managed care & specialty pharmacy · 2020
    PMID: 32020843PMCID: PMC10390935DOIFirst author27 citations

Publications

170 publications

Funding

6 grants
Completed grants (6)
  • Sub-PI
    Diabetic Retinopathy Clinical Research Network
    National Eye Institute · 2014–2024 · via Jaeb Center for Health Research, Inc.
    U10EY014231
  • KP
    The Annexin A2 Pathway in Proliferative Vitreoretinopathy: A New Therapeutic Target
    U.S. Department of Defense · 2021–2024
    No publications yet
    W81XWH2110390-01
  • Co-I
    AAV-Based Gene Therapy for the Long-Term Treatment of CLN2-Associated Retinal Degeneration and Prevention of Blindness in CLN2 Patients
    Daedalus Fund for Innovation (Weill Cornell) · 2021–2023BioPharma Alliance
    BP 214968-01
  • Co-I
    Corneal Confocal Microscopy Quantitative Imaging of Corneal Nerves as a Biomarker of Neurologic Disease in Friedreich's Ataxia
    Friedreich's Ataxia Research Alliance · 2019–2021
    FARA 194201-01
  • KP
    Annexin A2 in Proliferative Vitreoretinopathy
    U.S. Department of Defense · 2014–2018
    W81XWH-14-1-0507
  • KP
    Preclinical Development of Genetically-Delivered Bevacizumab for Treatment of Wet Macular Degeneration
    National Eye Institute · 2013–2014 · via REGENX Bio, Inc.
    R43EY023108-01

Clinical research

1 study
Completed & closed trials (1)
  • PI
    A Phase 2, Randomized Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
    PHASE2 · Ionis Pharmaceutical · IRB STUDY CLOSURE (as of 2021)
    Macular Degeneration; Geographic Atrophy
    NCT03815825

News mentions

  • Weight-Loss Drug Linked to Lower Risk of Eye Disease in Patients with Diabetes
    February 11, 2026

    The popular diabetes and weight-loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. The findings may offer comfort to patients concerned about their eye health while taking the drug.

  • Faculty Honored with Notable Awards
    May 15, 2025

    Weill Cornell Medicine faculty members were honored with awards for their exemplary achievements in medical research, education and care May 14-15 during Weill Cornell Medicine’s commencement activities.

  • Department of Defense Funds Research on Rare Eye Condition
    November 19, 2021

    Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense (DoD) to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.

External relationships

Leadership Roles

Capsida Biotherapeutics, Inc.

Other

Eli Lilly and Company · Optos, Inc. · Regeneron Pharmaceuticals, Inc.